Recent Investment Analysts’ Ratings Changes for Nurix Therapeutics (NRIX)

Several analysts have recently updated their ratings and price targets for Nurix Therapeutics (NASDAQ: NRIX):

• 12/11/2024 – Nurix Therapeutics had its price target raised by analysts at HC Wainwright from $30.00 to $35.00. They now have a “buy” rating on the stock.
• 12/10/2024 – Nurix Therapeutics is now covered by analysts at BTIG Research. They set a “buy” rating and a $35.00 price target on the stock.
• 12/10/2024 – Nurix Therapeutics had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $29.00 price target on the stock.
• 12/6/2024 – Nurix Therapeutics is now covered by analysts at BMO Capital Markets. They set an “outperform” rating and a $35.00 price target on the stock.
• 11/6/2024 – Nurix Therapeutics had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $29.00 price target on the stock.
• 10/24/2024 – Nurix Therapeutics is now covered by analysts at UBS Group AG. They set a “buy” rating and a $35.00 price target on the stock.

Nurix Therapeutics Trading Up 1.3 %

NASDAQ:NRIX traded up $0.25 during mid-day trading on Monday, hitting $20.08. The stock had a trading volume of 74,197 shares, compared to its average volume of 908,672. The company has a 50 day simple moving average of $23.46 and a 200-day simple moving average of $22.33. The stock has a market capitalization of $1.42 billion, a price-to-earnings ratio of -6.90 and a beta of 2.11. Nurix Therapeutics, Inc. has a 52 week low of $7.65 and a 52 week high of $29.56.

Nurix Therapeutics (NASDAQ:NRIX) last released its quarterly earnings results on Friday, October 11th. The company reported ($0.67) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.67). The company had revenue of $12.59 million during the quarter, compared to analysts’ expectations of $13.85 million. Nurix Therapeutics had a negative return on equity of 63.39% and a negative net margin of 313.65%. As a group, equities research analysts anticipate that Nurix Therapeutics, Inc. will post -2.81 earnings per share for the current year.

Insider Buying and Selling

In related news, insider Christine Ring sold 3,290 shares of the stock in a transaction that occurred on Monday, October 14th. The shares were sold at an average price of $25.00, for a total transaction of $82,250.00. Following the completion of the sale, the insider now directly owns 24,592 shares of the company’s stock, valued at $614,800. This represents a 11.80 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Houte Hans Van sold 3,546 shares of Nurix Therapeutics stock in a transaction that occurred on Friday, November 1st. The stock was sold at an average price of $24.28, for a total transaction of $86,096.88. Following the completion of the transaction, the chief financial officer now owns 33,724 shares in the company, valued at approximately $818,818.72. This trade represents a 9.51 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 18,401 shares of company stock valued at $437,453 over the last three months. Company insiders own 7.20% of the company’s stock.

Hedge Funds Weigh In On Nurix Therapeutics

Institutional investors have recently bought and sold shares of the stock. Amalgamated Bank raised its position in Nurix Therapeutics by 30.6% during the third quarter. Amalgamated Bank now owns 2,182 shares of the company’s stock valued at $49,000 after buying an additional 511 shares during the period. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Nurix Therapeutics by 31.6% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,330 shares of the company’s stock worth $54,000 after purchasing an additional 559 shares in the last quarter. Quarry LP boosted its holdings in shares of Nurix Therapeutics by 3,746.2% during the third quarter. Quarry LP now owns 2,500 shares of the company’s stock worth $56,000 after purchasing an additional 2,435 shares during the period. International Assets Investment Management LLC grew its position in Nurix Therapeutics by 1,098.4% during the third quarter. International Assets Investment Management LLC now owns 4,494 shares of the company’s stock valued at $101,000 after purchasing an additional 4,119 shares in the last quarter. Finally, Quest Partners LLC increased its stake in Nurix Therapeutics by 21.3% in the 3rd quarter. Quest Partners LLC now owns 7,458 shares of the company’s stock valued at $168,000 after buying an additional 1,312 shares during the period.

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.